Wyeth Pharmaceuticals Selects Tripos for Next-Generation Discovery IT Solution; New Scientific Workbench, Based on Tripos’ SMART-IDEA Technology, to Be Key Component of Wyeth’s Ongoing Strategy to Fill Its Drug Pipeline
Tripos, Inc., a leading provider of drug discovery chemistry and informatics products and services, today announced that Wyeth Pharmaceuticals, a division of Wyeth, has chosen Tripos discovery informatics technology as the basis for its next-generation discovery IT solution to be used by scientists throughout Wyeth’s worldwide discovery operations.
Under the terms of this agreement, Tripos is expected to receive approximately $5 million in software license and professional services fees over the next 12-18 months, with certain payments contingent upon the successful achievement of project milestones.
Wyeth’s new Scientific Workbench, along with a related integrated data repository, will facilitate cross-team collaboration to improve the way Wyeth scientists capture, manage and use key scientific data to efficiently make decisions. The workbench is based on Tripos’ SMART-IDEA(TM) technology, the solution Tripos developed in collaboration with Bristol-Myers Squibb Co. (BMY) and then deployed throughout that pharmaceutical company’s U.S. and Canadian research facilities.
Through the use of SMART-IDEA technology, discovery scientists can quickly combine data from disparate sources and analyze it using an integrated palette of decision-support tools, thus providing a virtual environment in which biologists, chemists and project leaders can view, share and act on important discovery data.
“Despite the many recent advances made in pharmaceutical research, there is still a significant unmet need for access to integrated discovery data necessary for optimal decision making,” said Bryan Koontz, senior vice president and general manager of Discovery Informatics at Tripos. “SMART-IDEA allows visionary pharmaceutical companies like Wyeth to maximize resources by dismantling data silos, enhancing the flow of discovery data between project teams and providing the analysis environment to enable more informed strategic decisions.”
The analysis and design portion of this project is already underway, and Tripos expects this first phase of the solution to be deployed to Wyeth’s scientists in fall 2006.
About Tripos, Inc.
Tripos (Nasdaq:TRPS) combines leading-edge technology and innovative science to deliver consistently superior, chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Within Tripos’ Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos’ Discovery Research (DR) business, Tripos’ medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Further information on Tripos can be found at http://www.tripos.com .
Tripos and the Tripos logo are registered trademarks of Tripos, Inc., and/or its affiliates in the United States and certain other countries.
All other trademarks mentioned in this document are the property of their respective owners.
